Biodel News
Most Popular Biodel Story
Linjeta - FDA's Top 10 Blockbuster Decisions
Drug: LinjetaCompany: BiodelPDUFA date: Oct. 30Peak sales: Difficult to project Discussions about Biodel's (BIOD) fast-acting insulin Linjeta (a new name for what Biodel had called VIAject) often
Read more...Latest Headlines
- November 1, 2010
- October 11, 2010
- September 8, 2008
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
